Inhibrx Biosciences Inc

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded on January 8, 2024 and is headquartered in La Jolla, CA.

SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide (IRI/TMZ) for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Inhibrx presented this dataset as of the data cut of September 8 th, 2023 at the Annual Connective Tissue Oncology Society (CTOS) Conference today.

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences: Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting November 1 st – 4th, 2023 – Dublin, Ireland Title: The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma: Preliminary Data From A Phase 1 StudyLead Author: Rashmi Chugh, MDPoster presentation on Thursday, November 2 nd, 2023 from 5:30 PM – 6:30 PM Irish Standard TimeLocation: The Liffey Convention Centre in Dublin, Ireland Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting November 3 rd – 5th, 2023 – San Diego, California Title: Phase 1/2 Study of the Bispecific 4-1BB and PD-L1 Antibody INBRX-105 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Jong Chul Park, MDAbstract: 742Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center, San Diego, CA - Hall A Presentation Title: Phase 1/2 Study of the Hexavalent OX40 Agonist INBRX-106 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Rachel E. Sanborn, MDAbstract: 748Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center in San Diego, CA - Hall A The posters will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations upon commencement of each respective presentation.

Inhibrx Announces Participation in Upcoming Scientific Conferences

SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD").

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% following a private placement financing agreement.

Andreas Halvorsen's Firm Ups Inhibrx Stake

SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Management as the lead investor, Viking Global Investors, Perceptive Advisors, and TCGX.

Inhibrx Announces $200 Million Private Placement Financing

INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth in the coming years. INBRX-101 has received Fast Track designation from the FDA for the treatment of emphysema.

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2023 and provided an update on recent corporate highlights. Recent Corporate Highlights On May 30, 2023, Inhibrx announced that the U.S. Food and Drug Administration granted Fast Track designation to INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for the treatment of patients with emphysema due to alpha-1 antitrypsin deficiency, or AATD.

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

SAN DIEGO , May 30, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for the treatment of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD). Fast Track designation is granted by the FDA upon the request of the sponsor to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening diseases.

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.80 per share a year ago.

Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates

SAN DIEGO , May 8, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2023 and provided an update on recent corporate highlights. Recent Corporate Highlights On April 26, 2023, Inhibrx announced the initiation of a registration-enabling trial for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for treatment of patients with emphysema due to alpha-1 antitrypsin deficiency.

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?

SAN DIEGO , April 26, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has initiated a registration-enabling trial for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for treatment of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD). Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies evaluating its death-receptor 5 (DR5) agonist, INBRX-109.

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Inhibrx, Inc. develops biologics for rare diseases and oncology. It has two potentially registrational trials in the works. Cash balance is also decent.

Inhibrx: Undercovered Company With Good Potential

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates

SAN DIEGO , March 6, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2022. Key Highlights INBRX-101: Timing for the potentially registration-enabling trial for Alpha-1 Antitrypsin Deficiency, or AATD, is on track with sites expected to activate and initiate enrollment in April 2023.

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

BELOIT, Wis. & SAN DIEGO--( BUSINESS WIRE )--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced a collaboration to develop and produce novel radiopharmaceuticals for the treatment of cancer.

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming virtual investor conference: The Evercore ISI 5th Annual HealthCONx Conference Wednesday, November 30 th at 8:45 a.m. Pacific Time The investor conference presentation will be webcast live for at least 60 days following the event and will be accessible through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations.

Inhibrx Announces Participation in Upcoming Investor Conference

Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.

Inhibrx (INBX) Down on Updated Data From Bone Cancer Study

SAN DIEGO , Nov. 16, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma. Inhibrx presented this dataset as of May 2022 at the Annual Connective Tissue Oncology Society (CTOS) Conference today, which included matured data on the original chondrosarcoma cohort and initial data from an additional cohort of chondrosarcoma patients with the isocitrate dehydrogenase (IDH) mutation.

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 10.89% and 60.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates

SAN DIEGO , Nov. 7, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the third quarter of 2022 and provided an update on recent corporate highlights. Recent Corporate Highlights On August 15, 2022, Inhibrx announced that the European Commission, based on a positive opinion issued by the European Medicines Agency, has granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Following a rough outing throughout much of this year, biopharmaceutical firm Inhibrx (NASDAQ: INBX ) finally gave stakeholders reason to smile. Earlier today, the company announced it discussed with the Food and Drug Administration (FDA) matters associated with its key therapeutic INBRX-101.

Why Is Inhibrx (INBX) Stock Soaring 45% Today?

The shares of Inhibrix Inc (NASDAQ:INBX) are soaring today, up 41.1% at $28.48 at last glance, after the company alluded to potentially accelerated U.S. Food & Drug Administration (FDA) approval of its treatment for rare lung disease.

Biotech Stock Soars on Potential FDA Fast-Track

SAN DIEGO , Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint. Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients tested in the Phase 1 study.

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

– Event to be webcast live on Tuesday, October 4, 2022 at 5:30 a.m. PT – SAN DIEGO , Oct. 3, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it will host a live webcast presentation on Tuesday, October 4, 2022 at 5:30 a.m.

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

News for Inhibrx Biosciences Inc Stock (INBX)